What Is NAD+ and Why Does It Matter After 35?
Comparison of Prices, Services & Prescribing Standards Finals
You're Only $50.00 Away From Free Shipping!
Comparison of Prices, Services & Prescribing Standards Finals
I started paying attention to NAD+ research about two years ago, when I was building the formulation strategy for Live 5AM. What struck me was not the hype but the consistency: researchers from completely different labs kept arriving at the same finding. The molecule declines with age, the decline is measurable, and there are now well-characterized pathways for supporting it. This post is my attempt to explain what the science actually says, without the marketing spin.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell that carries electrons during energy production and fuels enzymes that regulate DNA repair and gene expression. Levels decline progressively from roughly age 30 onward, primarily because aging tissues consume NAD+ faster than the body replaces it, driven by increased DNA repair activity and a rise in NAD+-degrading enzymes linked to age-related inflammation.
NAD+ stands for nicotinamide adenine dinucleotide. The name is a mouthful, but the function is straightforward: it is a coenzyme, meaning a small molecule that enzymes need in order to do their jobs.
Every cell in your body contains NAD+, and it operates in two primary roles:
Electron carrier during metabolism. When your body converts food (glucose, fat, amino acids) into usable energy (ATP), that process involves a series of chemical reactions in which electrons are passed from one molecule to another. NAD+ accepts those electrons, becomes NADH, and then delivers them to the mitochondria, where they power the final stage of ATP production. Without adequate NAD+, this shuttle system slows down and cells produce energy less efficiently.
Fuel for regulatory enzymes. Two classes of enzymes consume NAD+ as part of their activity: sirtuins (SIRT1-7) and PARPs (poly ADP-ribose polymerases). Sirtuins regulate gene expression, inflammation, circadian rhythm, and DNA repair, but they can only operate when NAD+ is available. They literally use it up during their work. PARPs are DNA repair enzymes that respond to strand breaks and oxidative damage, and they also draw heavily on the NAD+ pool when damage levels are high.
The short version: NAD+ is the molecule that connects your food to your energy, and connects your DNA damage to its repair.
This is where the research gets interesting, and where the common explanation gets it slightly wrong.
The decline is not primarily about your body producing less NAD+. The biosynthetic machinery that makes NAD+ from precursors (including from vitamin B3 and amino acids) stays relatively intact with age. The problem is on the consumption side: aging tissues burn through NAD+ faster than the body can replenish it.
Two mechanisms drive this:
Increased PARP activity. Over decades, DNA accumulates damage from UV exposure, environmental toxins, and ordinary metabolic byproducts. Each repair event requires PARP enzymes, and each PARP activation consumes NAD+. A 2024 review in Aging Cell confirmed that NAD+ metabolism is directly involved in cellular senescence, the process by which damaged cells stop dividing and start producing inflammatory signals (Chini et al., 2024).
Rising CD38 activity. CD38 is an enzyme that degrades NAD+ as a byproduct of its signaling role. Research in aged animal models shows CD38 levels rise substantially with age-related inflammation. More CD38 means more NAD+ is degraded for reasons unrelated to useful cellular work. Some researchers now describe CD38 as a major culprit in age-related NAD+ depletion.
The result is a progressively shrinking NAD+ pool even in otherwise healthy people. A 2023 review in the International Journal of Molecular Sciences summarized findings from multiple tissue studies showing measurable declines in NAD+ concentrations across skeletal muscle, brain, liver, and blood from the third decade of life onward (Mateuszuk et al., 2023).
Reduced NAD+ availability has downstream effects on the enzymatic systems that depend on it. Researchers are careful to describe these as associations rather than proven causal relationships in humans, and that framing is worth keeping.
What observational and preclinical evidence links to lower NAD+ availability:
Mitochondrial function. Mitochondria are the organelles that produce ATP, and they require a steady NAD+ supply to run efficiently. Studies in aged animal models show that mitochondrial output declines alongside NAD+ levels, and that restoring NAD+ levels improves mitochondrial function in those models. Human data is more limited, but consistent with the direction of effect.
DNA repair capacity. If NAD+ is scarce, PARP enzymes that depend on it may not have adequate substrate to complete repairs efficiently. Over time, unrepaired DNA damage accumulates, and damaged cells may enter senescence (the "zombie cell" state) or malfunction.
Sirtuin activity. Sirtuins are sometimes called longevity genes because of the range of processes they regulate: inflammation, stress response, circadian biology, and epigenetic gene control. They are NAD+-dependent. When the NAD+ pool shrinks, sirtuin activity may decline in parallel.
What researchers are careful not to claim: that supplementing NAD+ levels will reverse these effects, treat any disease, or extend human lifespan. The human evidence for functional outcomes is promising but still growing, and the research community is explicit about what remains to be established through larger, longer trials.
There is no standard clinical test for NAD+ levels that most people can access routinely. Research studies use blood or muscle biopsies and specialized laboratory assays. So this question is more practical than diagnostic.
The honest answer is that declining NAD+ does not produce symptoms that clearly distinguish it from general age-related fatigue or reduced recovery. Researchers use biomarkers and population studies rather than symptom checklists.
What the evidence does support: NAD+ research is most relevant to people in their mid-30s and beyond, given that measurable decline typically begins in that period. The research focus is on support for cellular processes that change over time, not on treating specific symptoms or conditions.
If you are looking at NAD+ support as part of a broader cellular health strategy (alongside adequate sleep, exercise, and a diet with plenty of antioxidant-rich plants), the research context makes sense. If you are looking for a shortcut around those fundamentals, the evidence does not support that framing.
The two most evidence-backed strategies in current research are lifestyle and precursor supplementation.
Exercise. Physical activity is consistently associated with higher NAD+ levels in skeletal muscle. The mechanism involves activation of AMPK (an energy sensor) and PGC-1alpha pathways, which promote NAD+ biosynthesis and efficient mitochondrial function. This is not a reason to skip supplements and only exercise, but it is a reason not to treat supplements as a substitute for movement.
NAD+ precursors. The clinical approach with the most human trial data involves providing the body with the raw materials to make NAD+. The two most studied precursors are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), both forms of vitamin B3. Multiple randomized controlled trials have shown that both NR and NMN raise blood NAD+ levels in adults, typically by 40-90% at studied doses. A 2018 study in Nature Communications found chronic NR supplementation was well tolerated and effectively raised NAD+ in healthy middle-aged and older adults (Martens et al., 2018). A 2024 study confirmed acute NR supplementation also raises NAD+ in the brain in living humans, using magnetic resonance spectroscopy (Nanga et al., 2024).
Antioxidant-rich diet and polyphenols. Oxidative stress is one of the drivers of increased PARP activity and NAD+ consumption. Plant polyphenols (found in berries, green tea, grapes, and pomegranate) have documented antioxidant effects in humans and may reduce background oxidative burden on cells. Some, like resveratrol, have also been studied for potential interactions with sirtuin enzymes, though human evidence on that specific mechanism is mixed.
At Live 5AM, the NAD+ question led us to formulate the NAD+ Booster Complex as a 6-ingredient product built around nicotinamide riboside (NR) as the foundation, with additional plant-based support layers.
The NR component is the one with direct regulatory approval: Health Canada licenses it as a source of vitamin B3 that helps maintain blood NAD+ levels and supports cellular health (NPN 80145698). The supporting ingredients (resveratrol, quercetin, grape seed extract, hawthorn, and pomegranate extract) are included for their antioxidant and complementary roles, each with their own approved claims.
The daily dose is three capsules (one with each main meal), providing 300 mg of NR per day alongside the supporting ingredients. This aligns with the lower range of doses studied in human trials. Health Canada's licensed directions note to use for a minimum of two months to see beneficial effects, which is consistent with how clinical trials measure outcomes.
In the Live 5AM Daily Pace framework, we position NAD+ Booster Complex in the morning and midday windows, paired with the energy and focus support ingredients that make the most sense earlier in the day. If you are using NMN 600 separately, it occupies the same precursor role; the two products are not designed to be stacked together, as both address the NAD+ pathway via vitamin B3 precursors.
The product is manufactured in Canada and holds an active Health Canada NPN, which matters in a category where many options ship from the US without regulatory approval for the claims they make.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in every cell that powers energy production and fuels enzymes that regulate DNA repair and gene expression. Levels decline from roughly age 30 onward primarily because aging tissues consume NAD+ faster than the body replaces it. Accumulated DNA damage activates PARP repair enzymes that use NAD+ heavily, and an NADase enzyme called CD38 rises with age-related inflammation and degrades NAD+ more aggressively. The result is a progressively smaller NAD+ pool over time.
Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors and forms of vitamin B3 that the body converts to NAD+ inside cells. NR converts to NMN first, then to NAD+. Head-to-head human trials are limited, but evidence through 2025 suggests both raise blood NAD+ comparably at equivalent doses. NR has a slight edge in oral bioavailability data; more recent large-scale NMN trials show dose-dependent NAD+ increases. For most people, either is a valid approach; the clinical evidence bases are similar in quality.
Resveratrol does not directly raise NAD+ levels. Its proposed role is as a sirtuin activator: laboratory studies show it interacts with the SIRT1 enzyme complex and may help sirtuins function more efficiently when NAD+ is available. Human trials on sirtuin expression have shown variable results. Resveratrol's antioxidant effects are well-established in humans independently of the sirtuin mechanism, which is why antioxidant claims are the ones with the clearest regulatory support.
Quercetin is a plant flavonoid studied for its antioxidant effects and its potential as a senolytic compound that may help clear senescent ("zombie") cells that accumulate with age. Senescent cells release inflammatory signals that elevate CD38 and PARP activity, both of which consume NAD+. In theory, supporting senescent cell clearance may reduce this burden on the NAD+ pool. Most human senolytic evidence uses higher doses than typical supplements; antioxidant benefits are the most directly applicable at standard supplemental doses.
Human clinical trials using NAD+ precursors typically see measurable blood NAD+ increases within two to four weeks of consistent use. Health Canada's licensed directions for NR-based supplements note to use for a minimum of two months to see beneficial effects, which aligns with how clinical trials measure functional outcomes. Single-dose use may raise NAD+ transiently, but the cellular benefits observed in trials reflect sustained supplementation over weeks and months.
NAD+ is one of the most thoroughly researched molecules in the cellular health field, and the science around its decline with age is among the most consistent findings in aging biology. The primary mechanism (increased consumption by PARP and CD38 enzymes as DNA damage and inflammation accumulate) is well characterized, and the precursor strategy for supporting blood NAD+ levels has solid human trial evidence behind it.
What the evidence does not yet support are dramatic claims: that supplementing NAD+ will reverse aging, treat disease, or guarantee specific health outcomes. The research community is explicit that causality in humans is still being established for many of the downstream effects observed in preclinical models.
What the evidence does support is that nicotinamide riboside, as a source of vitamin B3, helps maintain blood NAD+ levels to support cellular health, and that this effect is measurable, well-tolerated, and reproducible across multiple human studies. For anyone in their mid-30s or beyond who is thinking about cellular health as a long-term priority, NAD+ support is one of the more evidence-grounded areas in the supplement category.
This post is for informational purposes only and does not constitute medical advice. NAD+ Booster Complex is a licensed natural health product (NPN 80145698) and is not intended to diagnose, treat, cure, or prevent any disease or health condition. If you have a medical condition, are pregnant or breastfeeding, or are taking medications including cardiac glycosides or blood pressure medications, consult a health care practitioner before use.